Announcements Trials

Browse Landscape

Phase

Phase NA 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Prostatic Neoplasms 2 Breast Neoplasms 2 Overweight 1 Obesity 1 Melanoma 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Vitamin D 2 Tirzepatide 2 Metformin 2 licogliflozin 1 indole-3-carbinol 1 bupropion hydrochloride, naltrexone hydrochoride drug combination 1 Tablets 1 Specimen Handling 1 Resistance Training 1 Progestins 1 Pregabalin 1 Orlistat 1 Organizational Objectives 1 Omeprazole 1 Observation 1 Naltrexone 1 Ketorolac 1 Exergaming 1 Exercise 1 Exenatide 1 Diet, Plant-Based 1 Dexmedetomidine 1 Dalteparin 1 Counseling 1 Cholecalciferol 1 Calcium Citrate 1 Calcium Carbonate 1 Calcitriol 1 CKD732 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Obesity × Naltrexone × Clear all

NCT04499950 2025-03-06

A-NEW

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed

53 enrolled 14 charts

Breast Neoplasms, Obesity, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon ⚡